Moshayedi Natalie, Clair Kiran, Francoeur Alex A
California University of Science and Medicine, Colton, CA, USA.
University of California, Irvine, Irvine, CA, USA.
Gynecol Oncol Rep. 2025 Aug 24;61:101929. doi: 10.1016/j.gore.2025.101929. eCollection 2025 Oct.
Obesity is a well-established risk factor for endometrial cancer, driven by chronic inflammation, insulin resistance, and excess estrogen. As the global obesity epidemic continues to worsen, effective weight management plays a crucial role in reducing both incidence and progression. Recent pharmacotherapy advancements, particularly GLP-1 receptor agonists, show promising weight loss effects by modulating appetite and metabolism. Preclinical studies suggest these agents may also influence cancer progression, though further clinical research is needed. Bariatric surgery remains the most effective long-term intervention for severe obesity, offering significant metabolic and hormonal benefits. Weight loss surgery is associated with reduced cancer risk and improvements in molecular markers, though findings on specific biomarkers remain inconsistent. This narrative review explores emerging weight loss interventions, focusing on novel pharmacologic agents and bariatric surgery, and their impact on endometrial cancer risk and outcomes.
肥胖是子宫内膜癌公认的危险因素，由慢性炎症、胰岛素抵抗和雌激素过多所致。随着全球肥胖流行情况持续恶化，有效的体重管理对降低发病率和疾病进展起着关键作用。近期药物治疗方面的进展，尤其是胰高血糖素样肽-1（GLP-1）受体激动剂，通过调节食欲和新陈代谢显示出有前景的减肥效果。临床前研究表明这些药物可能也会影响癌症进展，不过还需要进一步的临床研究。减肥手术仍然是治疗重度肥胖最有效的长期干预措施，具有显著的代谢和激素方面的益处。减重手术与降低癌症风险及分子标志物改善有关，尽管关于特定生物标志物的研究结果仍不一致。本叙述性综述探讨了新兴的减肥干预措施，重点关注新型药物和减肥手术，以及它们对子宫内膜癌风险和预后的影响。
